Coherus BioSciences Inc
(NAS:CHRS)
$
0.73
0.06 (8.96%)
Market Cap: 84.11 Mil
Enterprise Value: 187.54 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 39/100 
Coherus BioSciences Inc at UBS BioPharma Conference Transcript
Nov 09, 2023 / 04:30PM GMT
Release Date Price:
$1.6
(-21.18%)
Ashwani Verma
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst
Okay. Good day everybody. My name is Ash Verma. I'm a SMID cap biotech and spec pharma analyst at UBS. And with me today is the Coherus team. With us, Denny Lanfear, who's the CEO; Paul Reider, Chief Commercial Officer; and Theresa Lavallee, who is the Chief Development Officer. Thanks for joining us.
Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO
Thank you very much for the invitation to the conference, and we're happy to talk to you today, Ash.
Ashwani Verma;Dennis M. Lanfear
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst;Coherus BioSciences, Inc. - Chairman, President &
Great. So just maybe start off like with a quick, very brief outline for the company for people that might not be familiar, just like take a couple of quick minutes and then to the questions.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers